Kura Oncology Announces Positive Phase 1 Kidney Cancer Data
SAN DIEGO – July 27, 2026 Kura Oncology, Inc. has reported updated Phase 1a clinical data from the ongoing...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SAN DIEGO – July 27, 2026 Kura Oncology, Inc. has reported updated Phase 1a clinical data from the ongoing...
HOUSTON, Texas & TÜBINGEN, Germany — December 11, 2025 — Immatics N.V. announced compelling Phase 1a dose-escalation data for...
BOSTON, Massachusetts, October 14, 2025 — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) today announced encouraging preliminary data from its completed...
